Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,otherAssets,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,totalCashflowsFromInvestingActivities,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,priceHint,shortName,exchange,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,exchangeDataDelayedBy,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,marketState,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,HSDT,7146000.0,2317360,1377000,,-5981000,,-5981000,4744000,4000,-6166000,-6166000,,,,,,0,71000,6237000,67000,185000,,-5981000,-5981000,438000.0,138023000.0,2350000.0,8367000.0,290000.0,10717000.0,2000.0,-128246000.0,213000.0,783000.0,-1412000.0,7425000.0,2137000.0,-1412000.0,511000.0,8985000.0,220000.0,507000.0,912000.0,,-2000.0,-186000.0,-291000.0,6000.0,-3972000.0,-17000.0,-3769000.0,62000.0,-23000.0,-2000.0,-192000.0,2468000.0,,,6848000.0,en-US,US,EQUITY,True,Delayed Quote,14.4863,1630526403,0.36630058,14.4,14.5,14.1501,7666,-0.8575115,-0.055886474,33720196,-96.57533,2.8150604,15,America/New_York,EDT,-14400000,False,False,USD,2,"Helius Medical Technologies, In",NCM,5.146,15.064029,-0.5777283,-0.03835151,15.343812,0,finmb_266639642,NasdaqCM,"Helius Medical Technologies, Inc.",USD,22875,10300,3.4863005,0.3169364,11.0 - 34.0,-19.513699,-0.5739323,11.0,34.0,1609718400,1621281600,1621281600,1621281600,-8.569,-0.15,PRE,2.5941968,14.1501 - 14.5,14.12,0.0,0.0,8,12,us_market,0.84,,,34.0,11.0,15.06,15.34,22.88k,10.3k,2.32M,,1.93M,14.60%,26.17%,84.87k,12.32,3.88%,3.66%,97.43k,,,,,,0.00%,"Jan 03, 2021",,1:35,"Jan 03, 2021","Dec 30, 2020","Jun 29, 2021",0.00%,"-3,422.64%",-105.08%,-208.02%,477k,0.27,-46.60%,273k,-15.96M,-15.36M,-8.57,,7.42M,3.2,62k,0.74,4.20,5.15,-11.45M,-5.69M,Value,18940,Healthcare,19,"Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.",Newtown,215 944 6100,PA,1609372800,United States,http://heliusmedical.com,86400,642 Newtown Yardley Road,Medical Devices,Suite 100
t-1,HSDT,10650000.0,2317360,1316000,,-3362000,,-3362000,2197000,69000,-3501000,-3501000,,,,,,0,84000,3585000,15000,139000,,-3362000,-3362000,479000.0,135388000.0,2766000.0,11898000.0,284000.0,14664000.0,2000.0,-122265000.0,216000.0,769000.0,-1227000.0,11397000.0,2534000.0,-1227000.0,553000.0,12863000.0,203000.0,484000.0,1093000.0,,233000.0,11020000.0,-217000.0,12351000.0,8066000.0,-12000.0,-2921000.0,100000.0,-95000.0,36000.0,-1331000.0,384000.0,-21000.0,-19000.0,10329000.0,en-US,US,EQUITY,True,Delayed Quote,14.4863,1630526403,0.36630058,14.4,14.5,14.1501,7666,-0.8575115,-0.055886474,33720196,-96.57533,2.8150604,15,America/New_York,EDT,-14400000,False,False,USD,2,"Helius Medical Technologies, In",NCM,5.146,15.064029,-0.5777283,-0.03835151,15.343812,0,finmb_266639642,NasdaqCM,"Helius Medical Technologies, Inc.",USD,22875,10300,3.4863005,0.3169364,11.0 - 34.0,-19.513699,-0.5739323,11.0,34.0,1609718400,1621281600,1621281600,1621281600,-8.569,-0.15,PRE,2.5941968,14.1501 - 14.5,14.12,0.0,0.0,8,12,us_market,0.84,,,34.0,11.0,15.06,15.34,22.88k,10.3k,2.32M,,1.93M,14.60%,26.17%,84.87k,12.32,3.88%,3.66%,97.43k,,,,,,0.00%,"Jan 03, 2021",,1:35,"Jan 03, 2021","Dec 30, 2020","Jun 29, 2021",0.00%,"-3,422.64%",-105.08%,-208.02%,477k,0.27,-46.60%,273k,-15.96M,-15.36M,-8.57,,7.42M,3.2,62k,0.74,4.20,5.15,-11.45M,-5.69M,Value,18940,Healthcare,19,"Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.",Newtown,215 944 6100,PA,1609372800,United States,http://heliusmedical.com,86400,642 Newtown Yardley Road,Medical Devices,Suite 100
t-2,HSDT,2585000.0,2317360,827000,,-2535000,,-2535000,2087000,-10000,-3000000,-3000000,,,,,,0,191000,3191000,201000,465000,,-2535000,-2535000,527000.0,123872000.0,2676000.0,3871000.0,281000.0,6547000.0,1000.0,-118903000.0,220000.0,759000.0,-1099000.0,3331000.0,2424000.0,-1099000.0,576000.0,4685000.0,230000.0,389000.0,747000.0,,266000.0,2911000.0,-277000.0,1949000.0,651000.0,-40000.0,-2171000.0,103000.0,-22000.0,26000.0,962000.0,268000.0,-49000.0,-49000.0,2261000.0,en-US,US,EQUITY,True,Delayed Quote,14.4863,1630526403,0.36630058,14.4,14.5,14.1501,7666,-0.8575115,-0.055886474,33720196,-96.57533,2.8150604,15,America/New_York,EDT,-14400000,False,False,USD,2,"Helius Medical Technologies, In",NCM,5.146,15.064029,-0.5777283,-0.03835151,15.343812,0,finmb_266639642,NasdaqCM,"Helius Medical Technologies, Inc.",USD,22875,10300,3.4863005,0.3169364,11.0 - 34.0,-19.513699,-0.5739323,11.0,34.0,1609718400,1621281600,1621281600,1621281600,-8.569,-0.15,PRE,2.5941968,14.1501 - 14.5,14.12,0.0,0.0,8,12,us_market,0.84,,,34.0,11.0,15.06,15.34,22.88k,10.3k,2.32M,,1.93M,14.60%,26.17%,84.87k,12.32,3.88%,3.66%,97.43k,,,,,,0.00%,"Jan 03, 2021",,1:35,"Jan 03, 2021","Dec 30, 2020","Jun 29, 2021",0.00%,"-3,422.64%",-105.08%,-208.02%,477k,0.27,-46.60%,273k,-15.96M,-15.36M,-8.57,,7.42M,3.2,62k,0.74,4.20,5.15,-11.45M,-5.69M,Value,18940,Healthcare,19,"Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.",Newtown,215 944 6100,PA,1609372800,United States,http://heliusmedical.com,86400,642 Newtown Yardley Road,Medical Devices,Suite 100
t-3,HSDT,1893000.0,2317360,1327000,,-3477000,,-3477000,2370000,109000,-3660000,-3660000,,,,,,0,131000,3791000,22000,183000,,-3477000,-3477000,579000.0,120213000.0,2829000.0,3197000.0,339000.0,6026000.0,45000.0,-116368000.0,217000.0,725000.0,-693000.0,2680000.0,2565000.0,-693000.0,568000.0,4136000.0,218000.0,572000.0,720000.0,18000.0,296000.0,2911000.0,260000.0,1949000.0,-2584000.0,15000.0,-2588000.0,97000.0,-2000.0,-31000.0,962000.0,269000.0,-11000.0,-11000.0,1571000.0,en-US,US,EQUITY,True,Delayed Quote,14.4863,1630526403,0.36630058,14.4,14.5,14.1501,7666,-0.8575115,-0.055886474,33720196,-96.57533,2.8150604,15,America/New_York,EDT,-14400000,False,False,USD,2,"Helius Medical Technologies, In",NCM,5.146,15.064029,-0.5777283,-0.03835151,15.343812,0,finmb_266639642,NasdaqCM,"Helius Medical Technologies, Inc.",USD,22875,10300,3.4863005,0.3169364,11.0 - 34.0,-19.513699,-0.5739323,11.0,34.0,1609718400,1621281600,1621281600,1621281600,-8.569,-0.15,PRE,2.5941968,14.1501 - 14.5,14.12,0.0,0.0,8,12,us_market,0.84,,,34.0,11.0,15.06,15.34,22.88k,10.3k,2.32M,,1.93M,14.60%,26.17%,84.87k,12.32,3.88%,3.66%,97.43k,,,,,,0.00%,"Jan 03, 2021",,1:35,"Jan 03, 2021","Dec 30, 2020","Jun 29, 2021",0.00%,"-3,422.64%",-105.08%,-208.02%,477k,0.27,-46.60%,273k,-15.96M,-15.36M,-8.57,,7.42M,3.2,62k,0.74,4.20,5.15,-11.45M,-5.69M,Value,18940,Healthcare,19,"Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.",Newtown,215 944 6100,PA,1609372800,United States,http://heliusmedical.com,86400,642 Newtown Yardley Road,Medical Devices,Suite 100
